Primary Sjögren's syndrome (pSS) can affect various organs, sometimes leads to life-threatening conditions and is always responsible for a decreased quality of life. Its evolution is chronic, with flares and relapses, and the need for reliable biomarkers to be carried out routinely is major in patients' follow-up. Because of the existence of autoreactive immunoglobulins E (IgE) in autoimmune diseases, the recently described role for anti-Ro/SSA antibodies in inducing interferon alpha (IFNα) signaling and the specific pharmacologic properties of IgE, anti-Ro/SSA IgE should be an interesting biomarker to determine pSS's activity. The aim of the study is to evaluate whether the proportion of anti-Ro/SSA IgE positive patients is higher in patients with active disease (i.e. Eular Sjögren Syndrome Disease Activity Index≥ 5). All consecutive patients with pSS (new or already known diagnosis) will be included, Anti-Ro/SSA IgE titers will be determined, the disease's features will be collected (including Eular Sjögren Syndrome Disease Activity Index/Eular Sjogren's Syndrome Patient Reported Index).
Study Type
OBSERVATIONAL
Enrollment
185
Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
CH Pierre Oudot
Bourgoin, France
NOT_YET_RECRUITINGCHU Estaing - Clermont Ferrand
Clermont-Ferrand, France
RECRUITINGCHU Grenoble Alpes
Grenoble, France
RECRUITINGHôpital de la Croix Rousse
Lyon, France
RECRUITINGCH Lyon Sud
Lyon, France
RECRUITINGHôpital Edouard Herriot - CHU Lyon
Lyon, France
NOT_YET_RECRUITINGCHU Reims
Reims, France
NOT_YET_RECRUITINGChu Saint-Etienne
Saint-Etienne, France
RECRUITINGProportion of anti-Ro/SSA IgE positive patients
Comparison of proportion of anti-Ro/SSA IgE positive patients between patients with active pSS and patient without active pSS anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Active pSS is defined by Eular Sjögren Syndrome Disease Activity Index (ESSDAI) ≥ 5
Time frame: Day 1
Correlation between anti-Ro/SSA IgE titers and pSS's activity.
pSS's activity is defined by Eular Sjögren Syndrome Disease Activity Index (ESSDAI). Anti-Ro/SSA IgE titers is measured by serial dilutions of the serum. Anti-Ro/SSA IgE titers is the last dilution whose absorbance (in optical density) is higher than positivity threshold.
Time frame: Day 1
Correlation between anti-Ro/SSA IgE positive patients and the symptomatology level
Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). The symptomatology level is measured by the Score Eular Sjogren's Syndrome Patient Reported Index (ESSPRI). If ESSPRI≥5: symptomatology whose intensity felt by the patient is not acceptable. If ESSPRI\<5: symptomatology whose intensity felt by the patient is acceptable.
Time frame: Day 1
Correlation between anti-Ro/SSA IgE positive patients and onset of lymphoma
Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). There is a medical monitoring every years by medical record and/or by phone know that a development of lymphoma.
Time frame: 5 years
Correlation between anti-Ro/SSA IgE positive patients and interferon alpha signature
Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Interferon alpha signature level is measured by real-time Polymerase Chain Reaction (PCR). They calculate the average of delta cycle threshold in messenger ribonucleic acid (mRNA) of regulate gene by interferon alpha.
Time frame: Day 1
Comparison between anti-Ro/SSA IgE positive patients and clinical and biologic characteristics
Anti-Ro/SSA IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Composite outcome of clinical and biologic characteristics is describe below. Clinical characteristics: type of affected organs, lymphoma medical history, allergic disorders, scores Eular Sjögren Syndrome Disease Activity Index (ESSDAI), Eular Sjogren's Syndrome Patient Reported Index (ESSPRI) and analogue visual scale disease patient and doctor, saliva flow and Schirmer test. Biologic characteristics: anti-Ro/SSA IgE titers, rheumatoid factor titers and number of totals lymphocytes and T cluster of differentiation 4 (CD4) lymphocytes.
Time frame: Day 1
Comparison between anti-La/SSB IgE positive patients and clinical and biologic characteristics
Anti-La/SSB IgE is measured by an indirect quantitative Enzyme Linked ImmunoSorbent Assay (ELISA). Composite outcome of clinical and biologic characteristics is describe below. Clinical characteristics: type of affected organs, lymphoma medical history, allergic disorders, scores Eular Sjögren Syndrome Disease Activity Index (ESSDAI), Eular Sjogren's Syndrome Patient Reported Index (ESSPRI) and analogue visual scale disease patient and doctor, saliva flow and Schirmer test. Biologic characteristics: anti-La/SSB IgE titers, rheumatoid factor titers and number of totals lymphocytes and T CD4 lymphocytes.
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.